HIV-1 infection kinetics, drug resistance, and long-term safety of pre-exposure prophylaxis with emtricitabine plus tenofovir alafenamide (DISCOVER): week 144 open-label extension of a randomised, controlled, phase 3 trial

Authors: Flamm, Jason A; Hare, Charles B | The Lancet. Hiv | August 1, 2024 | PubMed abstract

Explore all publications

Back To Top